Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.
about
Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000-2013Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.Chronic Myeloid Leukemia in Nigerian Patients: Anemia is an Independent Predictor of Overall SurvivalMinimal Residual Disease Eradication in CML: Does It Really Matter?First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients.Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase.Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death.BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia.Charlson comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor.Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission.Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012.Symptom Burden and Quality of Life Issues among Patients of Chronic Myeloid Leukemia on Long-term Imatinib TherapyImatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.DNA Methylation Events as Markers for Diagnosis and Management of Acute Myeloid Leukemia and Myelodysplastic Syndrome.Innovation in hematology. Perspectives: CML 2016Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.Raising the bar: the future of EGFR inhibition in non-small lung cancer.First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?Similar expression profiles in CD34+ cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib.CML - we are not there yet.Precision medicine: the foundation of future cancer therapeutics.First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysisPrecision oncology is not an illusion
P2860
Q35949910-4771B9F5-941E-4F7B-8450-46F4C9F1BABAQ36974374-20CE49C1-671A-412E-8422-DF94A820B779Q37025973-B7C6AAA8-4BA1-41BB-8DF9-A533240E04A6Q38602633-3776ECA3-B208-490E-9F8E-4B378EE89B80Q38620872-F71793CF-9FA5-495E-8DA1-CCB7CE9812DCQ38753313-4D902543-F6F6-4F22-A964-269967E88BB1Q38762572-C50188E5-A048-4945-8089-A8042ECE04C5Q38767908-7193C4D7-B3DB-41F9-A8FD-CE9A3DBCC577Q38963992-FBBAC710-DB3E-4708-8A3F-54748CA56DB7Q39350678-6037A419-1858-48BF-9ACF-BCB0F0224E82Q39661740-749935D8-F300-43CF-8F6C-1DCD30B216FEQ40302552-191B30F6-5858-493D-B973-E1AF9D02D21EQ40346616-5E73D261-AC7B-43D9-A738-0EDE5AFFE09FQ40519438-E071D4D8-9948-4B2F-9115-0D8FAA74FEDCQ40765997-FAB691EE-E2E9-41FD-A026-1B5E68B64F64Q40821920-77300BEF-E0F9-4C15-9D06-42079FC5FBDDQ41164222-D6A3534C-DF99-4F70-9BE6-F173CEDB8A24Q41601810-F5420F4A-E1E8-4690-8F70-07EF8E0EEC35Q42316987-BCEC1232-DF36-414A-9C4A-E739339EF39CQ42361215-8A71A33F-4FB7-491D-B247-568F744244ADQ42397473-9EC92260-7834-4F9C-8709-1B8B9BB18539Q47096076-B6F139FD-138F-4339-B6A3-121830CB1C3BQ47163753-A7F7E55E-585D-4CF8-AE82-D626F8840FF4Q47917650-5A24B5C4-D982-4246-AEDF-3E0ABB958D83Q48162932-F433F266-DD48-49E1-91AA-88EE1564873DQ50421953-0444A14A-E735-41F6-A880-D41FF706C981Q50997822-BA1451B3-D243-4A89-9461-13F9FB4EC511Q52715772-77E2544F-D73A-4C9D-8BC1-012EC9D2C66BQ55034957-E6075300-B6BE-4939-B50F-63897456C261Q55040682-B740854E-4206-4C0F-AA17-B47A451C0EEFQ57069646-691A9F4C-8615-4503-84FB-DE631FC692F3Q58928648-A56998CC-96D9-4B41-9A7B-24CE6045C025
P2860
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Impact of comorbidities on ove ...... f the randomized CML study IV.
@ast
Impact of comorbidities on ove ...... f the randomized CML study IV.
@en
type
label
Impact of comorbidities on ove ...... f the randomized CML study IV.
@ast
Impact of comorbidities on ove ...... f the randomized CML study IV.
@en
prefLabel
Impact of comorbidities on ove ...... f the randomized CML study IV.
@ast
Impact of comorbidities on ove ...... f the randomized CML study IV.
@en
P2093
P2860
P50
P1433
P1476
Impact of comorbidities on ove ...... f the randomized CML study IV.
@en
P2093
Andrea Bartholomäus
Andreas Burchert
Antonio Pezzutto
Benjamin Hanfstein
Dominik Heim
Doris Kraemer
Florian Zettl
Holger F Hebart
Ingo Schmidt-Wolf
Jochen Heymanns
P2860
P356
10.1182/BLOOD-2015-01-617993
P407
P577
2015-04-27T00:00:00Z